HHS Releases National Cancer Plan
“Plan Will Help Advance the President and First Lady’s Cancer Moonshot
Today, the U.S. Department of Health and Human Services (HHS) released a National Cancer Plan, developed by the National Institutes of Health’s (NIH) National Cancer Institute (NCI). The plan provides a framework for everyone—across the federal government and all of society—to collaborate in ending cancer as we know it, and to realize the vision laid out by President Joe Biden and First Lady Jill Biden’s Cancer Moonshot.”

Lung Cancer Survivors and Caregivers from Across the Country Head to Capitol Hill to Advocate for Increased Research Funding
“WASHINGTON, March 28, 2023 /PRNewswire/ — Tomorrow, more than 40 LUNG FORCE Heroes – people living with lung cancer, their loved ones and advocates from across the country – will head to Washington, D.C. to meet with members of Congress during the American Lung Association LUNG FORCE Advocacy Day. As a part of the event, LUNG FORCE Heroes will ask lawmakers to support $51 billion in research funding for the National Institutes of Health (NIH), $11.6 billion in funding for the Centers for Disease Control and Prevention (CDC) and to support and protect Medicaid.”

Lung Cancer Screening Rates Extremely Low, Worst Among the Commercially Insured
“Newswise — A new study from the Harvey L. Neiman Health Policy Institute found that only 1.8% of eligible Americans with commercial insurance received lung cancer screening.  Rates were higher but still extremely low for Original Medicare (3.4%) and Medicare Advantage (4.6%).  The study, published in the Journal of the American College of Radiology, determined 2017 screening rates for patients who were eligible for lung cancer screening by low-dose computed tomography (LDCT), as determined United States Preventive Services Task Force guidelines.”

Outcomes after first-line therapy for small cell lung cancer may vary by trial eligibility
“Overall treatment outcomes among patients with extensive-stage small cell lung cancer who received first-line chemoimmunotherapy appeared comparable to those reported in pivotal clinical trials, according to study results.”

Treatments Move Beyond Immunotherapy for SCLC
“In recent years, immunotherapy has shown to be the most promising treatment for patients with small cell lung cancer (SCLC). However, many challenges remain with these agents, including toxicity and efficacy, and more options are needed to properly treat different subtypes of this disease.”

New RYBREVANT® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
“COPENHAGEN, Denmark, March 29, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).

Arkansas Lung Cancer Survivor heads to Washington, D.C. for Lung Force Advocacy Day
LITTLE ROCK (KATV) — An Arkansas woman who survived lung cancer is in Washington, D.C. meeting with members of Congress during the American Lung Association’s Lung Force Advocacy Day.

9/11 first responder – who discovered he has Stage 4 lung cancer while on vacation – is convinced diagnosis is linked to time at Ground Zero
An Ohio man who was on a trip to San Diego received a life-changing cancer diagnosis that he believes is connected to his work at Ground Zero after the 9/11 terror attacks.

While in Louisville for the NCSS Sweet 16, WVUA 23 News met a special couple who traveled there for the first time so they could make some very special memories.

Reducing Disparities in the Care of Patients with Lung Cancer
A program created by a physician at The MetroHealth System allows clinicians to more quickly identify patients at high risk of lung cancer and improve their access to expedited diagnosis and care.

Patients with lung cancer, depression have higher inflammation levels
Moderate to severe depression in patients with lung cancer was linked to elevated inflammation levels, and the biomarkers measuring inflammation predicted poor survival, according to study results published in PLOS ONE.

Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer
“Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for NSCLC treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested. Meanwhile, the need for effective alternatives to lurbinectedin (Zepzelca) persists in the second-line setting for small cell lung cancer (SCLC), according to faculty from an OncLive® Institutional Perspectives in Cancer (IPC) webinar on lung cancer.”

New study supports saving more lung tissue in lung cancer surgeries
“The traditional treatment for early-stage non-small cell lung cancer is a lobectomy, where a surgeon eradicates cancerous tissue by removing an entire lung lobe.”


Hershey lung cancer patient turned advocate travels to DC
“HERSHEY, Pa. (WHTM) – Hershey resident and lung cancer advocate Summer Farmen traveled to Washington D.C. to meet with members of Congress during the American Lung Association’s “LUNG FORCE Advocacy Day.””

MetroHealth reveals new program allowing for earlier detection of lung cancer risks